- Mitsubishi Tanabe Pharma America (OTCPK:MTZPY -1.5%) initiates a Phase 3 clinical trial, BouNDless, evaluating continuous subcutaneously administered carbidopa/levodopa (ND0612) compared to the oral formulation in Parkinson's disease (PD) patients.
- The study will enroll ~300 PD sufferers who are experiencing motor fluctuations ("OFF" time at least two hours each day) that are no longer adequately controlled by conventional therapies.
- The primary endpoint is the change from baseline at week 12 in daily "ON" time without troublesome dyskinesia (uncontrolled movement). The estimated primary completion date is September 2020.
- The study design will be presented at the International Congress of Parkinson's Disease and Movement Disorders in Nice, France, September 22-26.
- Subsidiary NeuroDerm is leading clinical development.
- PD-related tickers: Seelos Therapeutics (SEEL -2.6%), Kyowa Kirin (OTCPK:KYKOF +2.3%), ProMIS Neurosciences (OTCQB:ARFXF), Cerecor (CERC +5%), Voyager Therapeutics (VYGR +2.2%), Anavex Life Sciences (AVXL +0.8%), Adamas Pharmaceuticals (ADMS -0.2%), Axovant Gene Therapies (AXGT +2.5%), Acorda Therapeutics (ACOR +1.5%), Newron Pharmaceuticals S.p.A. (OTCPK:NWPHF), Merck (MRK +0.2%), Bristol-Myers Squibb (BMY +0.4%)